Onapsis Announces New Offering to Jumpstart Security for SAP Customers
10.5.2022 16:00:00 EEST | Business Wire | Press release
Onapsis, the leader in business-critical application cybersecurity and compliance, today announced the release of Onapsis Assess Baseline. In a world where business-critical applications are under attack every day, this new offering accelerates organizations’ abilities to kickstart their SAP vulnerability management programs by better aligning with the SAP Security Baseline.
The exponential growth of targeted ransomware and the increased threat of cyber warfare due to global conflict means that organizations must re-evaluate how they secure their most critical systems. Amid this evolving, more aggressive threat landscape, companies struggle to keep up with patching the growing number of vulnerabilities exploited by threat actors to gain access to their business-critical applications. Onapsis Assess Baseline empowers companies of any size to accelerate time-to-value by simplifying deployment with a new SaaS-based, zero-footprint model and focusing on a core, targeted set of critical vulnerabilities as first steps on their journey to ensure cybersecurity, compliance, and availability of their SAP applications. When organizations are ready to take on more, Onapsis Assess Baseline offers easy expansion to additional scope for vulnerability management as well as capabilities for continuous threat monitoring and application security testing.
Key Organizational Benefits with Onapsis Assess Baseline:
- Reduce Implementation Overhead with an Accelerated Deployment: Whether in their own cloud, on-premises, or through Onapsis’ SaaS platform, Assess Baseline offers quick deployment and implementation with zero footprint scanning.
- Accelerate Time-to-Value for SAP Vulnerability Management: Onapsis SaaS users can scan with Assess Baseline against the SAP-recommended security baseline requirements for an organization’s SAP systems within hours. The scans deliver powerful context around critical vulnerabilities, instructions on how to mitigate, and confidence that patches were applied, saving valuable resource time.
- Technology that Scales and Grows When You’re Ready: Deploy where you want. Scan across the entire SAP landscape. Start small and target the most critical systems first, get them aligned to a baseline, and then expand the security scope across the organization on your terms.
“Securing business-critical applications has always been challenging, but there’s a larger bullseye on the backs of organizations today - more than ever before - as sophisticated threat actors increasingly target Enterprise Resource Planning (ERP) systems,” said Mariano Nunez, CEO of Onapsis. “We have successfully helped the world’s largest and most sophisticated organizations integrate their business applications into their cybersecurity and compliance programs. Now, Assess Baseline makes it easy for customers who are getting started with their SAP application security programs to quickly and effectively jumpstart protecting the applications that power their businesses.”
The Onapsis Platform secures the critical SAP applications that keep the global economy running. The platform is purpose-built to deliver impactful vulnerability management, advanced threat detection, custom code inspection, and automated compliance that enables global organizations to accelerate their business and digital transformation initiatives. The Onapsis Platform is deeply informed by the latest threat intelligence and security guidance from the Onapsis Research Labs. This market-leading team has discovered more than 800 zero-day vulnerabilities and is responsible for multiple critical global CERT alerts.
“Today’s threat landscape requires a holistic approach to securing business-critical SAP applications such as ERP software,” said Steve Biskie, national ERP risk and automation services leader with RSM US LLP. “It is exciting to see Onapsis continuing to innovate its solutions to assist companies on their security maturity journey. The new Baseline license can help pave the way for more organizations to have an entry point into vulnerability management for SAP applications that could help keep their critical data and applications safe and compliant.”
Attending the SAP Sapphire conference? Visit the Onapsis booth to learn more: #PA219
To schedule a time to speak with an Onapsis expert while at Sapphire, please visit: https://onapsis.com/sapphire-22
About Onapsis
Onapsis protects the business-critical applications that run the global economy, from the core to the cloud. The company’s cybersecurity and compliance solution offering, The Onapsis Platform, uniquely delivers vulnerability management, threat detection and response, change assurance, and continuous compliance for business-critical applications from leading vendors such as SAP, Oracle, Salesforce, and other SaaS platforms.
Onapsis is headquartered in Boston, MA, with offices in Heidelberg, Germany and Buenos Aires, Argentina, and proudly serves more than 300 of the world’s leading brands, including 20% of the Fortune 100, 6 of the top 10 automotive companies, 5 of the top 10 chemical companies, 4 of the top 10 technology companies, and 3 of the top 10 oil and gas companies.
The Onapsis Platform is powered by the Onapsis Research Labs, the team responsible for the discovery and mitigation of more than 800 zero-day vulnerabilities in business-critical applications. The reach of our threat research and platform is broadened through leading consulting and audit firms such as Accenture, Deloitte, IBM, PwC, and KPMG — making Onapsis solutions the standard in helping organizations protect their cloud, hybrid, and on-premises business-critical information and processes. For more information, connect with us on Twitter or LinkedIn, or visit us at https://onapsis.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005214/en/
Contact information
10Fold Communications for Onapsis
Mariah Simank, 512-971-3702
Onapsis@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
